Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-05-20 6:52 pm Sale |
2025-05-16 | 13D | XOMA Corporation XOMA |
BIOTECHNOLOGY VALUE FUND L P | 2,590,303 21.600% |
-392,723 (-13.17%) |
Filing History |
| 2025-05-19 6:42 pm Sale |
2025-05-15 | 13G | Allakos Inc. ALLK |
BIOTECHNOLOGY VALUE FUND L P | 0 0.000% |
-16,552,417 (Position Closed) |
Filing History |
| 2025-05-15 4:42 pm Purchase |
2025-03-31 | 13G | Vigil Neuroscience, Inc. VIGL |
BIOTECHNOLOGY VALUE FUND L P | 4,734,500 9.990% |
1,994,773 (+72.81%) |
Filing History |
| 2025-05-15 4:40 pm Purchase |
2025-03-31 | 13G | TScan Therapeutics, Inc. TCRX |
BIOTECHNOLOGY VALUE FUND L P | 5,263,541 9.990% |
190,538 (+3.76%) |
Filing History |
| 2025-05-15 4:37 pm Purchase |
2025-03-31 | 13G | Septerna, Inc. SEPN |
BIOTECHNOLOGY VALUE FUND L P | 4,396,124 9.900% |
1,944,100 (+79.29%) |
Filing History |
| 2025-05-15 4:35 pm Purchase |
2025-03-31 | 13G | iTeos Therapeutics, Inc. ITOS |
BIOTECHNOLOGY VALUE FUND L P | 3,075,000 8.100% |
750,000 (+32.26%) |
Filing History |
| 2025-05-15 4:33 pm Purchase |
2025-03-31 | 13G | Monte Rosa Therapeutics, Inc. GLUE |
BIOTECHNOLOGY VALUE FUND L P | 5,660,132 9.200% |
1,266,922 (+28.84%) |
Filing History |
| 2025-05-15 4:31 pm Sale |
2025-03-31 | 13G | GH Research PLC GHRS |
BIOTECHNOLOGY VALUE FUND L P | 8,827,712 14.200% |
-1,572,446 (-15.12%) |
Filing History |
| 2025-05-15 4:29 pm Sale |
2025-03-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT |
BIOTECHNOLOGY VALUE FUND L P | 4,632,749 9.990% |
-201,548 (-4.17%) |
Filing History |
| 2025-05-15 4:27 pm Sale |
2025-03-31 | 13G | Elevation Oncology, Inc. ELEV |
BIOTECHNOLOGY VALUE FUND L P | 4,440,000 7.000% |
-1,790,845 (-28.74%) |
Filing History |
| 2025-05-15 4:25 pm Purchase |
2025-03-31 | 13G | Cidara Therapeutics, Inc. CDTX |
BIOTECHNOLOGY VALUE FUND L P | 1,252,441 9.990% |
158,942 (+14.54%) |
Filing History |
| 2025-05-09 5:50 pm Unchanged |
2025-05-07 | 13D | Inventiva S.A. IVA |
BIOTECHNOLOGY VALUE FUND L P | 8,545,499 6.100% |
0 (Unchanged) |
Filing History |
| 2025-04-16 6:49 pm Sale |
2025-04-14 | 13G | Third Harmonic Bio, Inc. THRD |
BIOTECHNOLOGY VALUE FUND L P | 0 0.000% |
-2,372,933 (Position Closed) |
Filing History |
| 2025-04-09 09:00 am Unchanged |
2025-04-09 | 13D | ESSA Pharma Inc. EPIX |
BIOTECHNOLOGY VALUE FUND L P | 8,748,629 19.700% |
0 (Unchanged) |
Filing History |
| 2025-02-14 4:28 pm Purchase |
2024-12-31 | 13G | VistaGen Therapeutics, Inc. VTGN |
BIOTECHNOLOGY VALUE FUND L P | 3,084,324 9.970% |
307,079 (+11.06%) |
Filing History |
| 2025-02-14 4:26 pm Purchase |
2024-12-31 | 13G | Verastem, Inc. VSTM |
BIOTECHNOLOGY VALUE FUND L P | 4,706,551 9.990% |
427,030 (+9.98%) |
Filing History |
| 2025-02-14 4:24 pm Sale |
2024-12-31 | 13G | Tyra Biosciences, Inc. TYRA |
BIOTECHNOLOGY VALUE FUND L P | 3,944,194 7.800% |
-717,000 (-15.38%) |
Filing History |
| 2025-02-14 4:22 pm Sale |
2024-12-31 | 13G | Ikena Oncology, Inc. IKNA |
BIOTECHNOLOGY VALUE FUND L P | 4,006,564 8.300% |
-762,600 (-15.99%) |
Filing History |
| 2025-02-14 4:20 pm Sale |
2024-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT |
BIOTECHNOLOGY VALUE FUND L P | 4,834,297 9.990% |
-2,548,345 (-34.52%) |
Filing History |
| 2025-02-14 4:11 pm Purchase |
2024-12-31 | 13G | Forte Biosciences, Inc. FBRX |
BIOTECHNOLOGY VALUE FUND L P | 643,622 9.990% |
643,622 (New Position) |
Filing History |